

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY SHAREHOLDERS' MEETING

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) announces that at its 2026 first extraordinary shareholders’ meeting (the “**Shareholders’ Meeting**”) held on Thursday, September 24, 2026, all resolutions proposed were duly passed by way of poll. The Shareholders’ Meeting was convened by the board (the “**Board**”) of directors of the Company (the “**Directors**”).

Further details of the resolutions are set out in the notice of the Shareholders’ Meeting dated September 8, 2026 (the “**Notice**”) and the circular of the Company dated the same date (the “**Circular**”).

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY SHAREHOLDERS' MEETING

As at the date of verifying the Shareholders’ entitlement to attend the Shareholders’ Meeting, (i) the total number of the issued shares of the Company (the “**Shares**”) was 6,637,199,874 Shares, comprising 258,197,600 H Shares and 6,379,002,274 A Shares; and (ii) holders of 6,625,768,624 Shares (or by authorised proxies) were entitled to attend and vote on the resolutions proposed at the Shareholders’ Meeting. The total number of Shares for calculating the attendance of the Shareholders’ Meeting does not include the 11,431,250 A Shares repurchased and held in the stock repurchase account of the Company as treasury shares. The Company has not exercised the voting rights of the aforementioned Shares at the Shareholders’ Meeting. In addition, there were no Shares repurchased by the Company which are pending cancellation.

Each of Mr. Dai Hongbin, Mr. Zhang Lianshan, and Mr. Sun Jieping, being both participants of the 2026 A Share Employee Stock Ownership Scheme and Shareholders of the Company, as well as other relevant Shareholders interested in the 2026 A Share Employee Stock Ownership Scheme, were required to and have abstained from voting on resolutions in relation to the 2026 A Share Employee Stock Ownership Scheme (i.e. resolutions no. 1, 2 and 3) at the Shareholders’ Meeting. Accordingly, the total number of Shares which were required to and have abstained from voting on resolutions no. 1, 2 and 3 was 3,875,986 Shares.

In addition, as disclosed in the Circular, any Shareholders interested in the 2026 H Share Scheme were required to abstain from voting on resolutions in relation to the 2026 H Share Scheme (i.e. resolutions no. 4 and 5) at the Shareholders' Meeting. As at the date of the Shareholders' Meeting, the Company has not granted any Awards under the 2026 H Share Scheme. Accordingly, none of the Shareholders was required to abstain from voting on resolutions no. 4 and 5.

Save as disclosed above, to the best knowledge, information and belief of the Directors, no other Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the Shareholders' Meeting. Further, no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Shareholders' Meeting, and there were no Shares entitling the Shareholder to attend and abstain from voting in favor of the resolutions proposed at the Shareholders' Meeting as set out in Rule 13.40 of the Hong Kong Listing Rules.

ATTENDANCE AT THE SHAREHOLDERS' MEETING

The Board is pleased to announce that the Shareholders' Meeting was held on Thursday, September 24, 2026 at 2:30 p.m. at No. 1288, Haike Road, Pudong New Area, Shanghai, PRC.

All Directors and secretary to the Board attended the Shareholders' Meeting either in person or by electronic means.

Set out below are the details of the Shareholders and authorised proxies present at the Shareholders' Meeting:

Number of Shareholders and authorised proxies	8,544
<i>Including:</i>	
Number of A Shareholders	8,543
Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)	3,778,887,487
<i>Including:</i>	
Total number of Shares carrying voting rights held by A Shareholders (shares)	3,650,537,574
Total number of Shares carrying voting rights held by H Shareholders (shares)	128,349,913
Percentage of the total number of Shares carrying voting rights (%)	57.0332
<i>Including:</i>	
Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	55.0961
Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	1.9371

POLL RESULTS OF THE SHAREHOLDERS' MEETING

The poll results of the Shareholders' Meeting were as follows:

ORDINARY RESOLUTIONS		Number of votes cast (%)			Passed by Shareholders
		FOR	AGAINST	ABSTAIN	
1	To consider and approve the proposed adoption of the 2026 A Share Employee Stock Ownership Scheme	3,562,602,379 (94.2765%)	215,475,762 (5.7021%)	809,346 (0.0214%)	Yes
2	To consider and approve the proposed adoption of the Administrative Measures for the 2026 A Share Employee Stock Ownership Scheme	3,562,614,875 (94.2768%)	215,459,322 (5.7017%)	813,290 (0.0215%)	Yes
3	To consider and approve the proposed authorisation to the Board to deal with matters relating to the 2026 A Share Employee Stock Ownership Scheme	3,562,619,311 (94.2769%)	215,437,586 (5.7011%)	830,590 (0.0220%)	Yes
SPECIAL RESOLUTIONS		FOR	AGAINST	ABSTAIN	
4	To consider and approve, with or without amendments, the proposed adoption of the 2026 H Share Scheme	3,609,787,726 (95.5251%)	166,983,850 (4.4189%)	2,115,911 (0.0560%)	Yes
5	To consider and approve, with or without amendments, the proposed authorisation to the Board and/or the Administrator to handle matters relating to the 2026 H Share Scheme	3,609,866,119 (95.5272%)	166,929,157 (4.4174%)	2,092,211 (0.0554%)	Yes
6	To grant the Board, with or without amendments, a general mandate to repurchase H Shares not exceeding 10% of the total number of H Shares in issue (excluding any Treasury Shares) on the date of passing the special resolution according to special resolution No. 6 set out in the Circular	3,767,042,198 (99.6865%)	10,134,068 (0.2682%)	1,711,221 (0.0453%)	Yes

Notes:

- (1) Please refer to the Notice and Circular for details of these resolutions.
- (2) All percentages are rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.
- (3) An ordinary resolution is passed by more than half of the votes casted in favor of it.
- (4) A special resolution is passed by more than two-thirds of the votes casted in favor of it.

SCRUTINY OF VOTE-COUNTING AND LAWYER'S CERTIFICATION

Pursuant to the Hong Kong Listing Rules, Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of H Shares at the Shareholders' Meeting.

Grandall Law Firm (Nanjing) witnessed the Shareholders' Meeting and certified that the convening and holding procedures, qualification of the attendees and convenor as well as voting procedures and voting results of the Shareholders' Meeting conformed to the requirements of the relevant PRC laws, rules and regulations, guidelines, and the Articles of Association. The voting results were lawful and valid.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
September 24, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.